Browsing by Author "Kavakli, Kaan"

Now showing 1 - 5 of 5

The Association Between Hla Class I and Ii Alleles and The Occurrence of Inhibitors in Turkish Patients With Hemophilia A: a Pilot Study
(Wiley, 2019) Patiroglu, Turkan; Cansever, Murat; Akbayram, Sinan; Gulen, Huseyin; Oncel, Kahraman; Borst, Ozcan; Kavakli, Kaan
The Impact of Factor Viii Concentrate on the Development of Inhibitors in Children With Severe Hemophilia A: Turkish Pup Registry Study
(Wiley-blackwell, 2014) Kavakli, Kaan; Unuvar, Aysegul; Salcioglu, Zafer; Kilinc, Yurdanur; Oner, Ahmet Faik; Ay, Yilmaz; Zulfikar, Bulent
Incidence and Clinical Importance of Lupus Anticoagulant in Children With Recurrent Upper Respiratory Tract Infection
(Sage Publications inc, 2011) Peker, Erdal; Kavakli, Kaan; Balkan, Can; Karapinar, Deniz; Aydemir, Baran
Background: This study aims to understand the incidence and presence of lupus anticoagulant (LA) in children with recurrent upper respiratory tract infection (URTI). Methods: One hundred and sixty-five patients who were admitted to Departments of Pediatrics and Otolaryngology at Ege University Faculty of Medicine during the last 2 years and 120 age-matched healthy children as a control group were enrolled in the study. Results: The presence of LA in serum was positive in 8 (4.8%) cases in the patient group while only 2 (1.6%) cases in the healthy control group (P = .03). Mean age of patients with LA positive was significantly lower than those of negative cases (P = .02). Of the patients, 92 (55.8%) had adenoid hypertrophy. The annual frequency of URTI did not differ significantly between the LA patients and the LA-negative patients (7.5/year and 6.9/year, respectively). None of the patients with LA positive had adenoid hypertrophy (P = .009). Activated partial thromboplastin time was prolonged in 6 (3.6%) of 165 patients. Of these 6 patients, 2 were also LA positive. The presence of LA disappeared in all the 8 patients 2 months after the diagnosis. Lupus anticoagulant was found negative in all patients at the end of the second month. Conclusion: We found that the ratio of the presence of LA is higher in children with recurrent URTI than healthy children. However, the presence of LA does not lead to bleeding and/or thrombosis, and it disappears in a short period of time.
Retrospective Analysis of Hemophilia B in Turkey: Identifying Main Characteristics and Treatment Options
(Elsevier, 2024) Zulfikar, Bulent; Koc, Basak; Sahin, Fahri; Sasmaz, Hatice Ilgen; Kavakli, Kaan; Balkan, Can; Ar, Muhlis Cem
Background: Hemophilia B (HB), an X-linked recessive inherited bleeding disorder, exhibits a high prevalence among males. Objectives: To present the first national cohort of persons with HB to define the demographics, clinical characteristics, and treatment patterns in Turkey. Methods: This multicenter, retrospective study included 433 alive persons with HB registered in 35 centers between 1961 and 2018. Analyses were performed by age subgroups (0-17 years, 18-64 years, and >= 65 years), disease severity by factor levels (severe, <1 IU/dL; moderate, 1-5 IU/dL; mild, >5 IU/dL). Additionally, patients were stratified based on the initiation year of follow-up at the relevant study center, creating 2 periods: 1993-2006 (referred to as period A) and 2007-2018 (referred to as period B). Results: Predominantly male (98.6%), the median age at data entry was 22.1 years (n = 429). The majority (49.0%) had moderate HB, followed by severe (30.0%) and mild (15.7%) disease. Of the 377 patients with complete treatment details, 209 (55.4%) were under prophylaxis from their diagnosis onwards, while 79 patients (21.0%) only received on-demand treatment. Additionally, 89 patients (23.6%) initially underwent on-demand treatment and later were switched to prophylaxis. Knees were the primary site of bleeding and the most frequently intervened joints. Most of the major (47.5%) and minor (53.3%) orthopedic procedures were carried out in persons with severe HB, while half of radioactive synovectomy procedures were performed on persons with moderate HB. Conclusion: This paper describes the demographics, clinical characteristics, and treatments patterns of a large cohort of alive persons with HB on a national scale.
Use of a High-Purity Factor X Concentrate in Turkish Subjects With Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study
(Galenos Yayincilik, 2018) Oner, Ahmet F.; Celkan, Tiraje; Timur, Cetin; Norton, Miranda; Kavakli, Kaan
Hereditary factor X (FX) deficiency is a rare bleeding disorder more prevalent in countries with high rates of consanguineous marriage. In a prospective, open-label, multicenter phase 3 study, 25 IU/kg plasma-derived factor X (pdFX) was administered as on-demand treatment or short-term prophylaxis for 6 months to 2 years. In Turkish subjects (n=6), 60.7% of bleeds were minor. A mean of 1.03 infusions were used to treat each bleed, and mean total dose per bleed was 25.38 IU/kg. Turkish subjects rated pdFX efficacy as excellent or good for all 84 assessable bleeds; investigators judged overall pdFX efficacy to be excellent or good for all subjects. Turkish subjects had 51 adverse events; 96% with known severity were mild/moderate, and 1 (infusion-site pain) was possibly pdFX-related. These results demonstrate that 25 IU/kg pdFX is safe and effective in this Turkish cohort